Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 5Phase NA 3Phase 1/2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 6Myeloid 3Classical hematology 3Dermatologic 2Thoracic 1Plasma cell 1Breast 1

Conditions

Melanoma 2

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 37aldesleukin 26Interleukin-2 25Temozolomide 17fludarabine 16fludarabine phosphate 15trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Flow Cytometry × Dermatologic × Clear all
NCT00553306 2017-02-15

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Fred Hutchinson Cancer Center

Phase 1/2 Completed
10 enrolled
Dermatologic

Melanoma

NCT01082198 2013-08-26

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

National Cancer Institute (NCI)

Phase 1/2 Unknown
22 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡